| Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. Co.'s products include Biktarvy for the treatment of HIV-1 infection in certain patients, Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease, Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension. We show 42 historical shares outstanding datapoints in our coverage of GILD's shares outstanding history.|
Understanding the changing numbers of GILD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like GILD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching GILD by allowing them to research GILD shares outstanding history
as well as any other stock in our coverage universe.